Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 4, 2007, Pages 350-354

  Blum, William ^a   Porcu, Pierluigi ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Acute leukemia; Hyperleukocytosis; Hyperviscosity; Leukapheresis; Leukostasis

Indexed keywords

IMMUNOGLOBULIN M; PARAPROTEIN; PLASMA PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; APHERESIS; BLEEDING; BLOOD CLOTTING DISORDER; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; HYPERVISCOSITY SYNDROME; LEUKAPHERESIS; LEUKOCYTOSIS; LEUKOSTASIS; PATHOPHYSIOLOGY; PLASMA CELL DYSCRASIA; PLASMAPHERESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; WALDENSTROEM MACROGLOBULINEMIA;

BLOOD COMPONENT REMOVAL; BLOOD VISCOSITY; HUMANS; LEUKAPHERESIS; LEUKOCYTOSIS; PARAPROTEINEMIAS; PLASMA EXCHANGE; PLATELETPHERESIS; THROMBOPHILIA;

EID: 34249933504     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-976170     Document Type: Review

References (32)

1. Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000;39:1-18
2. Vaughan WP, Kimball AW, Karp JE, Dragon LH, Burke PJ. Factors affecting survival of patients with acute myelocytic leukemia presenting with high WBC counts. Cancer Treat Rep 1981;65:1007-1013
3. Hug V, Keating M, McCredie K, Hester J, Bodey GP, Freireich EJ. Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer 1983;52:773-779
4. Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol 1987;5:1364-1372
5. Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG, McCarthy LJ. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol 1997;98:433-436
6. Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer 1987;60:3071-3079
7. Bunin NJ, Pui CH. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol 1985;3:1590-1595
8. Bunin NJ, Kunkel K, Callihan TR. Cytoreductive procedures in the early management in cases of leukemia and hyperleukocytosis in children. Med Pediatr Oncol 1987;15:232-235
9. Cuttner J, Holland JF, Norton L, Ambinder E, Button G, Meyer RJ. Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia. Med Pediatr Oncol 1983;11: 76-78
10. Ventura GJ, Hester JP, Smith TL, Keating MJ. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol 1988;27:34-37
11. Giles FJ, Shen Y, Kantarjian HM, et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma 2001;42:67-73
12. Byrd JC, Mrozek K, Dodge R, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336
13. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100:4372-4380
14. Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994;84:3843-3849
15. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 1999;93: 3983-3993
16. Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988;71:123-131
17. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Causes of initial remission induction failure in acute myelogenous leukemia. Blood 1982;60:309-315
18. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336
19. Eguiguren JM, Schell MJ, Crist WM, Kunkel K, Rivera GK. Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis. Blood 1992;79:871-875
20. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24
21. Kuo KHM, Callum J, Brandwein J, et al. Management of hyperleukocytosis in acute myelogenous leukemia using hydroxyurea rather than leukopheresis. Blood 2006;108: (abst 2007)
22. McKee LC Jr, Collins RD. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Medicine (Baltimore) 1974;53:463-478
23. Novotny JR, Nuckel H, Duhrsen U. Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia. Eur J Haematol 2006;76:299-308
24. Novotny JR, Muller-Beissenhirtz H, Herget-Rosenthal S, Kribben A, Duhrsen U. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome. Eur J Haematol 2005;74:501-510
25. Stucki A, Rivier AS, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001;97:2121-2129
26. Kwaan HC, Bongu A. The hyperviscosity syndromes. Semin Thromb Hemost 1999;25:199-208
27. Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost 2003;29:467-471
28. Bachrach HJ, Myers JB, Bartholomew WR. A unique case of kappa light-chain disease associated with cryoglobulinemia, pyroglobulinemia, and hyperviscosity syndrome. Am J Med 1989;86:596-602
29. Rosenson RS, McCormick A, Uretz EF. Distribution of blood viscosity values and biochemical correlates in healthy adults. Clin Chem 1996;42:1189-1195
30. Drew MJ. Plasmapheresis in the dysproteinemias. Ther Apher 2002;6:45-52
31. Chirnside A, Urbaniak SJ, Prowse CV, Keller AJ. Coagulation abnormalities following intensive plasma exchange on the cell separator. Br J Haematol 1981;48:627-634
32. Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-979